Prognostic and immunological roles of Fc fragment of IgG binding protein in colorectal cancer

QUNCHUAN ZHUANG1,4*, ALING SHEN2,3*, LIYA LIU2,3, MEIZHU WU2,3, ZHIQING SHEN2,3, HUIXIN LIU2,3, YING CHENG2,3, XIAOYING LIN2,3, XIANGYAN WU2,3, WEI LIN2,3, JIAPENG LI2,3, YUYING HAN2,3, XIAOPING CHEN2,3, QI CHEN1,4 and JUN PENG2,3

1Biomedical Research Center of South China, Fujian Normal University, Fuzhou, Fujian 350117; 2Academy of Integrative Medicine; 3Fujian Key Laboratory of Integrative Medicine in Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122; 4Fujian Key Laboratory of Innate Immune Biology, Fujian Normal University, Fuzhou, Fujian 350117, P.R. China

Received November 6, 2020; Accepted May 6, 2021

DOI: 10.3892/ol.2021.12787

Abstract. Valuable diagnostic and prognostic biomarkers are urgently needed for colorectal cancer (CRC), which is one of the leading causes of mortality worldwide. Previous studies have reported altered expression of a mucin-like protein Fc fragment of IgG binding protein (FCGBP) in various types of cancer, but its potential diagnostic, prognostic and immunological roles in CRC remain to be determined. Therefore, the aim of current study was to investigate the potential roles of FCGBP in CRC. The present study investigated FCGBP mutations and changes in its expression levels using a combination of microarray and public dataset analyses, as well as immunohistochemistry. The results demonstrated a 10.5% mutation frequency in the FCGBP coding sequence in CRC tissues, and identified decreased FCGBP mRNA or protein expression levels in colorectal adenoma and CRC (compared with those in normal colorectal tissues from healthy control subjects), including pathologically advanced CRC (stage III+IV vs. I+II). Survival analysis using the GEPIA and Kaplan-Meier Plotter databases revealed that low FCGBP expression levels were associated with short overall, disease-free, relapse-free and metastasis-free survival times in patients with CRC. Notably, analysis using the online Tumor IMmune Estimation Resource database revealed a positive correlation between FCGBP expression levels and the extent of infiltrating immune cells, such as B cells and dendritic cells. Consistently, the expression levels of most markers (51/57) for various types of immune cells were significantly correlated with FCGBP expression levels in CRC tissues. These findings suggested that FCGBP may serve as a diagnostic and prognostic biomarker, and that FCGBP may be associated with immune infiltration in CRC.

Introduction

Globally, colorectal cancer (CRC) ranks third in incidence (10.0%) and second in cancer-related mortality (9.4%) among all types of cancer (1). In China, CRC is the fifth leading cause of death, with continuing increases in incidence (12.2%) and mortality (8.6%) (2). In addition, ~20% of patients with CRC present with distant metastases at the time of initial diagnosis (3). Despite notable advances in treatment strategies for CRC, such as surgery, chemotherapy and radiotherapy, >50% of patients with CRC develop metastasis, leading to a high mortality rate (4.5). Therefore, an improved understanding of the mechanisms underlying CRC pathogenesis is urgently needed to develop effective diagnostic and prognostic biomarkers and to identify potential therapeutic targets.

In our previous study, a gene expression profile microarray (GSE113513) was used to identify a panel of differentially expressed genes between 14 CRC and adjacent noncancerous colorectal tissue samples (6). Among these differentially expressed genes, the expression levels of Fc fragment of IgG binding protein (FCGBP) were lower in CRC tissue specimens compared with those in normal tissues. FCGBP, which was originally isolated from intestinal mucosa, is located on chromosome 19q13 and encodes a large mucin-like protein (>500 kDa) that binds the Fc region of IgG (7,8). FCGBP comprises numerous repeated domains, including 13 von Willebrand factor D, 12 cysteine-rich and 12 trypsin inhibitor-like domains (7-9). FCGBP is broadly expressed in various tissues, including the intestinal epithelium, gall bladder, cystic ducts, bronchi, submandibular glands and...
uterine cervix, as well as the fluids secreted by cells in these tissues (10).

Mutations and alternative splicing of FCGBP have been reported in hepatoblastoma (11) and lung cancer (12). Additionally, differential expression of FCGBP has been demonstrated to occur in various types of malignancies, including gall bladder (13), prostate (14), thyroid (15), lung (12) and ovarian (16) cancer as well as head and neck squamous cell carcinoma (17). FCGBP has been reported to be involved in cancer development and progression and is associated with patient survival in prostate (18), thyroid (19) and head and neck squamous cell (17) carcinoma, gall bladder cancer (13), ovarian adenocarcinoma (16) and osteosarcoma (20).

FCGBP was initially identified as a typical component of the mucus secreted by goblet cells, and low FCGBP levels have been observed in ulcerative colitis (21,22), colorectal adenoma (23), colorectal carcinoma (24-26) and CRC metastatic tissues (27-30). Low levels of FCGBP expression have also been reported to be associated with a short survival time in patients with CRC (27,28), suggesting that FCGBP may serve an important role in the development of CRC and may be used as a diagnostic and prognostic biomarker for CRC. In addition, FCGBP is an important component of immunological mucosal defenses (7). For example, Toxoplasma Gondii infection downregulates the expression levels of a number of secretory genes including FCGBP, which is involved in the transient disruption and reorganization of splenic architecture (31). However, the association between FCGBP expression and tumor immunity in CRC has not been reported to date. A previous study has revealed that goblet cells are not only secretory cells and that they uptake luminal material and deliver it to dendritic cells (DCs) in the lamina propria, suggesting a potential role for FCGBP in the immune response (32). In addition, as components of the tumor microenvironment, immune cells have been demonstrated to act as tumor promoters as well as suppressors (33). Considering their roles during tumor progression and recurrence, including metastasis and therapy resistance, immune cells are crucial determining factors in clinical outcomes and response to immunotherapy (34-36). Therefore, the present study aimed to determine the correlation of FCGBP expression levels with the numbers of immune cells and to assess its potential role as a target for immunotherapy in CRC.

Materials and methods

Gene expression profiling interactive analysis. Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/index.html) (37) is a web-based tool that includes 9,736 tumor and 8,587 normal tissue samples from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression projects. The FCGBP expression levels in the colon adenocarcinoma (COAD) dataset were obtained using matching normal tissue data in TCGA. The data were log2(TPM+1)-transformed for differential analysis, and the log2(fold-change) was defined as median (Tumor)-median (Normal). In the COAD dataset, the association between FCGBP mRNA expression levels and overall or disease-free survival was analyzed using the Kaplan-Meier method with the log-rank test. FCGBP expression levels in various CRC stages were compared by one-way analysis of variance to calculate differential FCGBP expression (http://gepia.cancer-pku.cn/detail.php?gene=FCGBP).

cBioPortal database analysis. The online cBioPortal tool (http://www.cbioportal.org), a software for interactive exploration of multiple cancer genomic datasets, was used to analyze FCGBP mutations in CRC samples.

Oncomine database analysis. Oncomine (http://www.oncomine.org) is an online platform that incorporates 264 independent datasets for 35 types of cancer and supports various analysis methods, including molecular concept, interactome and meta-analysis (38). FCGBP mRNA expression levels were compared in multiple datasets (Table I) (39-43) using the following filters: i) Gene, FCGBP; ii) analysis type, differential analysis of cancer vs. normal tissue; and iii) cancer type, CRC. The following thresholds were used: P-value, 0.05; fold-change, 2; and gene ranking, all.

R2 database analysis. R2 (http://r2.amc.nl), a web-based genomics analysis and visualization tool that contains gene microarray and RNA-Seq data (44), was used to analyze the association between FCGBP mRNA expression levels and disease-free, relapse-free and event-free survival. The following datasets were used: Tumor Colon - Smith - 232 MAS5.0 - u133p2, Tumor Colon - Sieber - 290 MAS5.0 - u133p2, Tumor Colon - SieberSmith - 355 MAS5.0 - u133p2, Tumor Colon MSI - status (Core-Transcript) - Sveen - 95 rna sketch - huex10t, Tumor Colon CIT (Combat) - Marisa - 566rma - u133p2 and Tumor Colon MVRM - SieberSmith - 345 rma(ubc) - u133p2.

Tumor IMMune Estimation Resource (TIMER) database analysis. As a comprehensive resource for systematic analysis of immune infiltrates in cancer, TIMER (https://cistrome.shinyapps.io/timer/) (45) includes 10,897 samples from 32 types of cancer in TCGA. Using the COAD dataset, the present study utilized TIMER to analyze the correlation of FCGBP expression levels with the extent of immune infiltrates including B cells, CD4+ and CD8+ T cells, neutrophils, macrophages and DCs, via gene modules. FCGBP expression levels based on tumor purity were also analyzed (46,47). The correlation module generated expression scatter plots between pairs of user-defined genes in CRC, performed Spearman's correlation analysis and estimated the statistical significance. Gene expression levels were displayed as log2(transcripts per million (TPM)) values. Correlations were analyzed between FCGBP expression and markers of tumor-infiltrating immune cells, including those for CD8+ T cells, T cells (general), B cells, monocytes, tumor-associated macrophages (TAMs), M1 and M2 macrophages, neutrophils, natural killer cells, DCs, T-helper 1 (Th1), T-helper 2 (Th2), follicular helper T (Tfh), T-helper 17 (Th17) cells, regulatory T cells (Tregs) and exhausted T cells (48-50).

Immunohistochemistry and image analysis. The tissue microarrays (TMAs) used in the present study (cat no. HColAd080CD01, containing 69 pairs of CRC tissues and adjacent noncancerous colorectal tissues; and HColA180Su15, containing four normal colorectal tissue, seven colorectal adenoma, seven primary and 10 metastatic CRC tissue
samples) were purchased from Shanghai Outdo Biotech Co., Ltd. For immunohistochemical staining, the slides were deparaffinized in xylene and rehydrated through graded ethanol series (100, 95, 90, 80 and 70%). Antigen retrieval was performed with 0.1% sodium citrate buffer (pH 6.0) for 20 min at 95°C. Endogenous peroxidase activity was quenched with 3% H$_2$O$_2$ in water, and nonspecific binding was blocked with PBS containing 1% bovine serum albumin (Beijing Solarbio Science & Technology Co., Ltd.) for 15 min at room temperature. Subsequently, the slides were sequentially incubated with an anti-FCGBP antibody (1:200; cat. no. ab217146; Abcam) at 4°C overnight, a ready-to-use biotinylated secondary antibody from the UltraSensitive S-P kit (Fuzhou Maixin Biotech Co., Ltd.) for 10 min at room temperature, and a ready-to-use horseradish peroxidase-conjugated streptavidin antibody from the UltraSensitive S-P kit for 10 min at room temperature. The slides were then incubated with the chromogen diaminobenzidine (Fuzhou Maixin Biotech Co., Ltd.) for 2 min at room temperature and counterstained with diluted Harris hematoxylin (Fuzhou Maixin Biotech Co., Ltd.) for 1 min. Images were captured using a Nano Zoomer 2.0 HT slide scanner (Hamamatsu Photonics K.K.) and processed using the Nano Zoomer Digital Pathology View 1.6 software (Hamamatsu Photonics K.K.). Immunohistochemistry scores in various tissue types were independently determined by two experienced pathologists blinded to the clinical and pathological data. Staining intensity and percentage of positively stained cells were determined as previously described (6). Scores of 4-12 and 0-3 were considered to indicate high and low FCGBP protein expression levels, respectively. All experiments were approved by the Ethics Committee of Fujian University of Traditional Chinese Medicine (Fujian, China).

**Statistical analysis.** Data are presented as the mean ± standard deviation. FCGBP expression is presented as log2(TPM+1)-transformed expression data in the plots. Statistical analyses were performed using SPSS 22.0 software (IBM Corp.). One-way ANOVA was performed to analyze FCGBP expression among pathological stages. Differences between paired CRC and adjacent or distant normal colorectal tissues were assessed using the Wilcoxon paired sample test. Differences between independent samples from two groups were assessed using the Mann-Whitney U test. Differences among three or more groups were assessed using the Kruskal-Wallis test with the Mann-Whitney test and the Bonferroni correction for pairwise comparisons. Differences in FCGBP mRNA expression levels between CRC and unpaired normal colorectal tissues in the Oncomine database were analyzed by the unpaired Student's t-test. The associations of FCGBP expression levels between patient groups were evaluated by the Fisher's exact test. Survival rates were determined using the Kaplan-Meier method and compared by the log-rank test. P<0.05 was considered to indicate a statistically significant difference.

### Table I. Oncomine analysis of Fc fragment of IgG-binding protein expression in colorectal cancer in seven colorectal cancer cohorts.

| Dataset             | Samples                        | Fold-change | P-value     | t-value   |
|---------------------|--------------------------------|-------------|-------------|-----------|
| **Kaiser Colon**    | Colon adenocarcinoma (n=41) vs. normal (n=5) | -8.454      | 3.78x10^{-15} | -11.938   |
|                     | Cecum adenocarcinoma (n=17) vs. normal (n=5) | -11.05      | 7.26x10^{-9}  | -9.516    |
|                     | Rectosigmoid adenocarcinoma (n=10) vs. normal (n=5) | -6.964      | 1.28x10^{-4}  | -5.559    |
|                     | Colon mucinous adenocarcinoma (n=13) vs. normal (n=5) | -2.574      | 0.001        | -3.604    |
|                     | Rectal adenocarcinoma (n=8) vs. normal (n=5) | -5.854      | 0.006        | -3.346    |
|                     | Rectal mucinous adenocarcinoma (n=4) vs. normal (n=5) | -9.213      | 0.013        | -3.979    |
| **TCGA colorectal** | Rectal adenocarcinoma (n=60) vs. normal (n=22) | -4.576      | 2.45x10^{-7}  | -19.081   |
|                     | Colon adenocarcinoma (n=101) vs. normal (n=22) | -4.157      | 9.00x10^{-25} | -20.029   |
|                     | Cecum adenocarcinoma (n=22) vs. normal (n=22) | -4.67       | 1.18x10^{-15} | -13.628   |
|                     | Colon mucinous adenocarcinoma (n=22) vs. normal (n=22) | -2.849      | 1.63x10^{-9}  | -8.163    |
|                     | Rectosigmoid adenocarcinoma (n=3) vs. normal (n=22) | -6.682      | 2.92x10^{-4}  | -14.447   |
|                     | Rectal mucinous adenocarcinoma (n=6) vs. normal (n=22) | -3.279      | 0.008        | -3.520    |
| **Skrzypczak colorectal** | Colon adenoma epithelia (5) vs. normal (10) | -11.298     | 2.57x10^{-9}  | -13.767   |
|                     | Colon carcinoma epithelia (n=5) vs. normal (n=10) | -42.143     | 1.43x10^{-9}  | -17.128   |
|                     | Colon adenoma (n=5) vs. normal (n=10) | -13.483     | 2.05x10^{-7}  | -9.422    |
|                     | Colon carcinoma (n=5) vs. normal (n=10) | -52.679     | 9.50x10^{-6}  | -9.689    |
| **Notterman colon** | Colon adenocarcinoma (n=18) vs. normal (n=18) | -4.521      | 2.68x10^{-5}  | -4.631    |
| **Hong colorectal** | Colorectal carcinoma (n=70) vs. normal (n=12) | -17.174     | 1.54x10^{-21} | -12.929   |
| **Skrzypczak colorectal** | Colorectal carcinoma (n=36) vs. normal (n=24) | -10.911     | 7.31x10^{-10} | -7.693    |
| **Gaedcke colorectal** | Rectal adenocarcinoma (n=65) vs. normal (n=65) | -11.899     | 1.00x10^{-14} | -9.755    |

TCGA, The Cancer Genome Atlas.
Results

Downregulation and mutations of FCGBP in CRC. To determine the differences in FCGBP expression between CRC and adjacent noncancerous tissues, FCGBP mRNA expression levels were compared in 14 matched pairs of primary CRC and noncancerous tissues using a cDNA array from our laboratory (GSE113513) (6). The results demonstrated a significant decrease in the FCGBP expression levels in the CRC tissues compared with those in the adjacent noncancerous colorectal tissues (P<0.05; Fig. 1A). The analysis of publicly available tumor expression data in GEPIA (P<0.05; Fig. 1B) and Oncomine (Table I) also revealed that the FCGBP mRNA levels were lower in the CRC tissues compared with those in the noncancerous tissues. The analysis of FCGBP mutations using cBioPortal revealed a somatic mutation frequency of 10.5% in the FCGBP DNA sequence (Fig. 1C). Furthermore, immunohistochemical analysis of a TMA demonstrated a significant decrease in the protein expression levels of FCGBP in the CRC tissues compared with the paired distal and adjacent noncancerous colorectal tissues (P<0.05; Fig. 2A), which was validated in another TMA comprising 69 pairs of CRC and adjacent noncancerous tissue samples (P<0.05; Fig. 2B). These results demonstrated a significant downregulation of FCGBP mRNA and protein levels in CRC tissues compared with those in noncancerous tissues.

Protein expression levels of FCGBP are decreased in colorectal adenoma and carcinoma tissues. CRC arises in preexisting adenomas, and death frequently occurs due to metastasis in patients with CRC (51). Therefore, the present study next determined the protein levels of FCGBP in colorectal adenoma and primary and metastatic CRC tissues by immunohistochemistry-based TMA analysis. Notably, the protein expression levels of FCGBP were significantly decreased in the colorectal adenoma tissues compared with those in the normal colorectal tissues from healthy controls (P<0.05; Fig. 3) and were comparable to those observed in the primary and metastatic CRC tissues. These results suggested that the decrease in the protein levels of FCGBP may serve a crucial role in malignant transformation during CRC development.

Downregulation of FCGBP expression in advanced-stage CRC tissues. To further assess FCGBP expression in CRC development, FCGBP mRNA expression levels were compared among CRC tissues from various pathological stages. The analysis of the COAD dataset in GEPIA revealed a gradual decrease in FCGBP mRNA expression levels in CRC tissues with advancing pathological stage (P<0.05; Fig. 4). The analysis of the associations of patient clinicopathological characteristics and the protein levels of FCGBP in CRC TMAs demonstrated that the protein levels of FCGBP were lower in advanced-stage CRC tissues compared with those in early-stage CRC tissues (Ⅲ+Ⅳ vs. Ⅰ+Ⅱ, P<0.05; Table II; Fig. 4B); however, a similar association was not observed with other clinicopathological parameters (Table II). Collectively, these results suggested that downregulation of FCGBP expression levels may be associated with advanced-stage CRC.

Downregulation of FCGBP predicts a shorter survival time in patients with CRC. The association between FCGBP expression levels and the survival times of patients with CRC was next analyzed in the COAD dataset using GEPIA. The Kaplan-Meier analysis demonstrated that low FCGBP mRNA levels were associated with a short overall survival (Fig. 5A), but not disease-free survival (P=0.07; Fig. 5B) in patients with CRC. Consistently, the survival analysis from multiple datasets using R2 confirmed the association between low FCGBP levels and short disease-free (Fig. 5C), event-free (Fig. 5D) and relapse-free (Fig. 5E-H) survival times in patients with CRC.

Figure 1. FCGBP mRNA levels are downregulated in CRC tissues. (A) FCGBP mRNA expression levels in 14 matched CRC and noncancerous colorectal tissue samples from our previously published gene expression microarray profile (GSE113513). (B) FCGBP expression in 275 CRC tissues and 41 noncancerous colorectal tissues from the COAD dataset analyzed by Gene Expression Profiling Interactive Analysis. Each datapoint represents one tissue sample; the error bars represent the mean ± standard deviation. *P<0.05. (C) Schematic representation of gene mutation sites in the coding sequence of FCGBP on the coding strand. Green dots indicate missense mutations, black dots indicate truncation sites, and brown dots indicate in-frame mutations. CRC, colorectal cancer; FCGBP, Fc fragment of IgG-binding protein; T, tumor; N, normal.


These data suggested that low FCGBP mRNA expression levels may serve as an indicator for the prognosis of CRC.

**Correlation between FCGBP expression levels and markers of immune infiltration in CRC.** Considering the roles of
ZHUANG et al: POTENTIAL ROLE OF FCGBP IN CRC

6

the present study investigated the relationship between FCGBP and immune infiltration in CRC. Correlation analysis using TIMER revealed that FCGBP expression levels were negatively correlated with tumor purity (r=-0.183; P<0.05) and macrophages (r=-0.149; P<0.05) and partially

Table II. Associations between FCGBP expression levels and the clinicopathological characteristics of patients with colon cancer.

| Characteristics     | n  | Low, n | High, n | Fisher’s P-value |
|---------------------|----|--------|---------|------------------|
| Total               | 93 | 46     | 47      |                  |
| Sex                 |    |        |         |                  |
| Male                | 51 | 25     | 26      | >0.999           |
| Female              | 42 | 21     | 21      |                  |
| Age, years          |    |        |         |                  |
| <65                 | 36 | 19     | 17      | 0.673            |
| ≥65                 | 57 | 27     | 30      |                  |
| Clinical stage      |    |        |         |                  |
| I+II                | 48 | 17     | 31      | 0.007<sup>a</sup>|
| III+IV              | 45 | 29     | 16      |                  |
| T stage             |    |        |         |                  |
| T1+T2               | 7  | 2      | 5       | 0.435            |
| T3+T4               | 86 | 44     | 42      |                  |
| N stage             |    |        |         |                  |
| N0                  | 57 | 28     | 29      | >0.999           |
| N1+N2               | 36 | 18     | 18      |                  |
| M stage             |    |        |         |                  |
| M0                  | 90 | 44     | 46      | 0.617            |
| M1                  | 3  | 2      | 1       |                  |
| Survival status     |    |        |         |                  |
| Alive               | 41 | 23     | 18      | 0.300            |
| Dead                | 52 | 23     | 29      |                  |
| Tumor size, cm      |    |        |         |                  |
| <5                  | 39 | 17     | 22      | 0.403            |
| ≥5                  | 54 | 29     | 25      |                  |

<sup>a</sup>P<0.05. FCGBP, Fc fragment of IgG-binding protein; T, tumor; N, node; M, metastasis.

Figure 4. Protein expression levels of FCGBP are downregulated in advanced-stage CRC tissues. (A) FCGBP mRNA expression in CRC tissues from different pathological stages in the COAD dataset was analyzed by Gene Expression Profiling Interactive Analysis. (B) The FCGBP protein expression in the different pathological stages of CRC tissues were analyzed in a commercially available TMA containing 93 CRC tissues. The representative images were taken at a magnification x4 and x20 and showed in the left panel. Each dot represents 1 tissue; median ± range; *P<0.05, vs. I + II stages. COAD, colon adenocarcinoma; CRC, colorectal cancer; FCGBP, Fc fragment of IgG-binding protein.
correlated with the levels of infiltrating B cells \( (r=0.192; \ P<0.05) \) and DCs \( (r=0.100; \ P<0.05) \); however, FCGBP expression was not correlated with the levels of infiltrating CD4\(^+\) and CD8\(^+\) T cells or neutrophils in CRC \( (all \ P>0.05; \ Fig. \ 6) \). These results suggested that FCGBP may be involved in the regulation of B cells and DCs, but not T cells, in CRC.

**Correlation between FCGBP expression and immune cell markers in CRC.** The present study further explored the potential relationship between FCGBP expression and infiltrating immune cells in the COAD dataset. Specific immune cell markers for CD8\(^+\) T and all T cells, B cells, TAMs, M1 and M2 macrophages, neutrophils, natural killer cells, DCs, Th1, Th2, Tfh and Th17 cells, Tregs and exhausted T cells in
Table III. Correlation analysis between FCGBP expression and associated immune cell markers using TIMER.

| Variables | No adjustment | Adjusted by tumor purity |
|-----------|---------------|--------------------------|
|           | r-value       | P-value                  | r-value       | P-value                  |
| CD8⁺ T cell |               |                          |               |                          |
| CD8A      | -0.021        | 0.492                    | -0.114        | 3.25x10⁻⁴a               |
| CD8B      | 0.035         | 0.248                    | -0.046        | 0.146                    |
| T cell (general) |           |                          |               |                          |
| CD3D      | 0.008         | 0.786                    | -0.098        | 0.002a                   |
| CD3E      | 0.001         | 0.966                    | -0.11         | 5.04x10⁻⁴a               |
| CD2       | -0.015        | 0.615                    | -0.122        | 1.10x10⁻⁴a               |
| B cell |               |                          |               |                          |
| CD19      | 0.007         | 0.007                    | -0.085        | 0.007a                   |
| CD79A     | -0.02         | -0.02                    | -0.132        | 2.98x10⁻⁴s               |
| CD86      | 0.163         | 0.163                    | 0.113         | 3.42x10⁻⁴a               |
| CSF1R     | 0.484         | 8.55x10⁻⁶6              | 0.462         | 1.06x10⁻⁴a               |
| B cell |               |                          |               |                          |
| CD19      | 0.007         | 0.007                    | -0.085        | 0.007a                   |
| CD79A     | -0.02         | -0.02                    | -0.132        | 2.98x10⁻⁴s               |
| CD86      | 0.163         | 0.163                    | 0.113         | 3.42x10⁻⁴a               |
| CSF1R     | 0.484         | 8.55x10⁻⁶6              | 0.462         | 1.06x10⁻⁴a               |
| Tumor-associated macrophage |           |                          |               |                          |
| CCL2      | 0.045         | 0.134                    | -0.027        | 0.394                    |
| CD68      | 0.117         | 9.67x10⁻⁵               | 0.072         | 0.023a                   |
| IL10      | -0.005        | 0.881                    | -0.068        | 0.033a                   |
| M1 macrophage |           |                          |               |                          |
| NOS2      | 0.121         | 5.48x10⁻⁵               | 0.113         | 3.40x10⁻⁴a               |
| IRF5      | 0.11          | 2.45x10⁻⁴4              | 0.076         | 0.017a                   |
| PTGS2     | 0.141         | 2.72x10⁻⁴6              | 0.077         | 0.015a                   |
| M2 macrophage |           |                          |               |                          |
| CD163     | 0.121         | 5.58x10⁻⁵               | 0.069         | 0.30a                    |
| VSIG4     | 0.3           | 2.35x10⁻²⁴              | 0.266         | 1.48x10⁻¹⁷a              |
| M2 macrophage |           |                          |               |                          |
| CD163     | 0.121         | 5.58x10⁻⁵               | 0.069         | 0.30a                    |
| VSIG4     | 0.3           | 2.35x10⁻²⁴              | 0.266         | 1.48x10⁻¹⁷a              |
| Neutrophil |               |                          |               |                          |
| CEACAM8   | 0.045         | 0.136                    | 0.034         | 0.285                    |
| ITGAM     | 0.309         | 9.46x10⁻²⁶              | 0.267         | 1.04x10⁻¹⁷a              |
| CCR7      | -0.004        | 0.885                    | -0.114        | 3.03x10⁻⁴a               |
| Natural killer cell |           |                          |               |                          |
| KIR2DL1   | -0.019        | 0.552                    | -0.078        | 0.014a                   |
| KIR2DL3   | -0.085        | 0.005                    | -0.133        | 2.78x10⁻⁵s               |
| KIR2DL4   | -0.137        | 5.52x10⁻⁶               | -0.199        | 2.71x10⁻¹⁰a              |
| KIR3DL1   | -0.017        | 0.563                    | -0.068        | 0.031a                   |
| KIR3DL2   | -0.036        | 0.227                    | -0.113        | 3.65x10⁻⁴a               |
| KIR3DL3   | -0.022        | 0.459                    | -0.068        | 0.033a                   |
| KIR2DS4   | -0.053        | 0.082                    | -0.086        | 0.006a                   |
| Dendritic cell |           |                          |               |                          |
| HLA-DPB1  | 0.294         | 1.42x10⁻²³              | 0.247         | 2.82x10⁻¹⁵a              |
| HLA-DQB1  | 0.207         | 5.02x10⁻¹²              | 0.136         | 1.79x10⁻⁵s               |
| HLA-DRA   | 0.214         | 7.76x10⁻¹³              | 0.154         | 1.11x10⁻⁶a               |
| HLA-DPA1  | 0.243         | 4.18x10⁻¹⁶              | 0.187         | 2.02x10⁻⁹a               |
| CD1C      | 0.328         | 4.84x10⁻²⁹              | 0.289         | 1.49x10⁻²⁰a              |
| NRP1      | 0.185         | 5.86x10⁻⁰⁰              | 0.128         | 5.19x10⁻⁵s               |
| ITGAX     | 0.224         | 4.97x10⁻¹⁴              | 0.176         | 2.49x10⁻⁸s               |
| T-helper 1 cell |           |                          |               |                          |
| TBX21     | -0.001        | 0.965                    | -0.102        | 0.001a                   |
| STAT4     | 0.031         | 0.304                    | -0.067        | 0.035a                   |
| STAT1     | -0.122        | 4.87x10⁻⁵               | -0.172        | 5.24x10⁻⁸s               |
| IFNG      | -0.086        | 0.004                    | -0.151        | 1.66x10⁻⁹a               |
| TNF       | 0.191         | 1.68x10⁻²⁰              | 0.158         | 5.63x10⁻⁷j               |
CRC were analyzed using TIMER. As presented in Table III, following adjustment for tumor purity, *FCGBP* expression levels were significantly correlated with 51 of the 57 immune cell markers in CRC. Notably, *FCGBP* expression levels were correlated with multiple markers of specific functional T cells, including the CD8^+^ T cell marker CD8A, all markers of all T cells (CD3D, CD3E and CD2), all markers of Th1 (TBX21, STAT4, STAT1, IFNG and TNF), a number of markers of Th2 (GATA3, STAT6, STAT5A), all markers of *BCL6* and *IL21*, Th17 marker STAT3, all markers of Tfh (BCL6 and IL21), Th17 marker STAT3, all markers of Tregs (FOXP3, CCR8, STAT5B and TGFB1) and all markers of exhausted T cells (PDCD1, CTLA4, LAG3, HAVCR2 and GZMB) (all *P* < 0.05). In addition, significant correlation was identified between *FCGBP* expression levels and a number of cell type-specific markers, including those for TAMs (CD68 and IL10), M1 (NOS2, IRF5 and PTGS2) and M2 (CD163 and VSG4) macrophages, suggesting that FCGBP may regulate macrophage polarization in CRC.

Consistent with the observed correlation between *FCGBP* expression levels and the extent of DC infiltration in the COAD dataset, all DC markers, including HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C, NRP1 and ITGAX, were also significantly correlated with *FCGBP* expression levels. These results further confirmed the association between FCGBP and DC infiltration. Similarly, the correlation between FCGBP levels and B cells in CRC was also observed based on B cell markers, including CD19, CD79A, CD86 and CSF1R. In addition, correlations were identified between FCGBP levels and markers of neutrophils (ITGAM and CCR7) or natural killer cells (KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3 and KIR2DS4). Therefore, these results demonstrated that FCGBP was significantly correlated with infiltrating immune cells in CRC, suggesting a potential role for FCGBP in immune infiltration in the CRC microenvironment.

**Discussion**

Studies of the underlying mechanisms of CRC pathogenesis are urgently needed to provide potential diagnostic and prognostic biomarkers, as well as therapeutic targets for CRC. The present study identified that CRC tissues exhibited low expression levels of FCGBP, which has been reported in various types of cancer, but its potential diagnostic, prognostic and immunological roles in CRC remain to be further explored. Therefore, the aim of current was to determine the potential roles of FCGBP in CRC. The current study provided evidence supporting the clinical relevance of FCGBP in CRC. Analytical
approaches based on microarrays, online databases and TMA immunohistochemistry revealed a significant decrease in FCGBP expression at the mRNA and protein levels in CRC tissues compared with those in noncancerous colorectal tissues, with 10.5% mutation frequency in the FCGBP coding sequence in CRC tissues. Furthermore, the protein expression levels of FCGBP were significantly decreased in colorectal adenoma and primary CRC tissues compared with those in normal colon tissues. In addition, low FCGBP expression levels, which were observed in advanced-stage CRC tissues, were significantly associated with a short survival time in patients with CRC. Notably, the results of the present study revealed that FCGBP expression levels were positively correlated with the levels of infiltrating B cells, macrophages and DCs, and negatively correlated with tumor purity in COAD. These results provided insights into the potential role of FCGBP in tumor immunology and suggested its potential use as a CRC biomarker as well as a therapeutic target.

Due to the relatively high percentage of patients with CRC and distant metastasis at the time of initial diagnosis (3), identification of novel and effective biomarkers for early diagnosis may contribute to the improvement of early screening for CRC. Omics technologies provide powerful methods to identify potential biomarkers for early diagnosis (53). Using microarray and online database analyses, the present study identified mutations and lower expression levels of FCGBP in CRC tissues compared with those in normal colorectal tissues, which was consistent with previous studies on various malignancies, including CRC (12-18,20,24-26). However, other data analysis approaches, including analysis of the original raw data using R or Python software, may provide additional information and will be used in our future studies.

Using immunohistochemistry-based TMA analysis, the present study validated the decreased protein levels of FCGBP in CRC tissues compared with those in proximal or distal adjacent noncancerous colorectal tissues and normal colorectal tissues. Further analysis of the protein levels of FCGBP among normal colorectal, adenomatous and carcinoma tissues confirmed the findings of a previous study in mice (23) by demonstrating that the levels of FCGBP were decreased in colorectal adenoma and CRC compared with those in normal colon tissues. These results suggested that the reduction in FCGBP levels may be a common event during CRC development, and that FCGBP may be considered as a potential biomarker for the early diagnosis of CRC. However, in the current study, no differences were identified in the protein expression of FCGBP between colorectal adenoma and CRC samples, which may be due to the limitations of IHC or the limited number of samples. Our future study will collect a larger number of samples to detect FCGBP expression levels.

The present study further assessed the associations between the protein levels of FCGBP and the clinicopathological characteristics of patients with CRC. Notably, the protein levels of FCGBP were lower in advanced-stage CRC samples compared with those in early-stage CRC, which was consistent with the results of the GEPIA analysis of FCGBP mRNA levels. Pairwise comparisons among different stages were not available on the GEPIA website, which was a limitation of the current study. However, these data indicated an association between low FCGBP expression levels and an advanced stage in CRC. Consistent with previous analyses of online databases (27,28), the results of the present study demonstrated that low FCGBP expression levels in CRC tissues were significantly associated with a short patient survival time, highlighting the potential role of FCGBP as a prognostic biomarker for CRC. However, due to the lack of survival information of patients with CRC included with the TMAs, the association between the protein expression levels of FCGBP and patient survival could not be validated in the present study. Patient samples and survival information will be collected to verify the results of the database analyses in our future studies. In addition, the aforementioned studies (27,28) and the current study have suggested that the decrease of FCGBP expression levels in tumors function as a promoting factor rather than being a concomitant phenomenon. Therefore, the unexplored biological function and underlying mechanism of the effects of FCGBP in CRC is a limitation of the current study, which should be further addressed in future studies.

FCGBP is secreted by various cell types, including intestinal goblet cells, and is considered to be an important component of mucosal immunological defenses (7). To analyze the roles of FCGBP in colorectal tumor immunology, the present study analyzed the correlation of FCGBP expression levels with the relative abundance of infiltrating immune cells, including B cells, CD4+ and CD8+ T cells, neutrophils, macrophages and DCs, via gene modules. The results of the systematic analysis of immune infiltrates in CRC using the TIMER database demonstrated that FCGBP expression levels were positively correlated with the infiltration levels of B cells, macrophages and DCs and negatively correlated with tumor purity; however, FCGBP expression levels were not correlated with CD4+ and CD8+ T cells or neutrophils in COAD. Collectively, these results suggested that FCGBP may serve an essential role in the regulation of infiltrating immune cells in COAD. Consistently, the results of the present study identified a significant correlation between FCGBP expression levels and multiple immune markers expressed in all tested infiltrating immune cell types in CRC. These results suggested a crucial role of FCGBP in immune cell infiltration into the CRC microenvironment. Although no significant correlations were identified between FCGBP levels and the relative abundance of CD4+ and CD8+ T cells or neutrophils in COAD, the results revealed correlations between FCGBP expression levels and the makers expressed by CD8+ T cells and neutrophils. Therefore, the correlations of FCGBP expression levels with immune cell infiltration levels and the expression of immune markers should be further addressed, and the biological function of FCGBP in the regulation of immune cell infiltration warrants further investigation.

In summary, in the present study, microarray and online database analyses were used to demonstrate that FCGBP expression levels were downregulated in colorectal adenoma and CRC, including advanced-stage CRC, compared with those in normal colorectal tissues from healthy subjects or paired adjacent noncancerous colorectal tissues, and that CRC tissue specimens harbored FCGBP mutations. In addition, low FCGBP expression levels were associated with a short survival time in patients with CRC. FCGBP expression levels were positively correlated with various tumor-infiltrating immune
cells and immune markers, suggesting that FCGBP may be involved in the regulation of immune cell infiltration into the CRC microenvironment. Overall, these results suggested that FCGBP may be a potential biomarker for the early diagnosis and prognosis of CRC. The precise role of FCGBP in immune cell infiltration requires further study.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81673721 and 81803882) and the International Cooperative Project of Fujian Department of Science and Technology (grant no. 2017I0007).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JP and QC conceived and designed the experiments. QZ, AS, MW, YC and LL conducted the bioinformatics analyses. AS, LL, XC, QZ and XL conducted the validation experiments. ZS, XW, JL and WL conducted data analysis. YH, HL and QZ conducted immunohistochemistry analysis and produced the figures. LL and MW confirm the authenticity of all the raw data. AS, QZ, QC and JP wrote and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The experiments were approved by the Ethics Committee of Fujian University of Traditional Chinese Medicine.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132, 2016.
3. Wang X and Li T: Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer. Bioengineered 11: 165-174, 2020.
4. Poturnajova M, Furrielova T, Balintova S, Schmidtova S, Kucerova L and Matasukova M: Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncol Rep 45: 10, 2021.
5. Siraj S, Masoodi T, Siraj AK, Azam S, Qadri Z, Ahmed SO, AlBalawy WN, Al-Obaissi KA, Parvathareddy SK, AlManea HM, et al: Clonal evolution and timing of metastatic colorectal cancer. Cancer Genet (Basel) 12: 2938, 2020.
6. Shen A, Chen Y, Liu L, Huang Y, Chen H, Qi F, Lin J, Shen Z, Wu X, Wu M, et al: EBF1-mediated upregulation of ribosome assembly factor PNO1 contributes to cancer progression by negatively regulating the p53 signaling pathway. Cancer Res 79: 2257-2270, 2019.
7. Kobayashi K, Ogata H, Morikawa M, Iijima S, Harada N, Yoshida T, Brown WR, Inoue N, Hamada Y, Ishii H, et al: Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids. Gut 51: 169-176, 2002.
8. Stamp LA, Braxton DR, Wu J, Akopian V, Hasegawa K, Chandrasoma PT, Hawes SM, McLean C, Petrovic LM, Wang K, et al: The GCTM-5 epitope associated with the mucin-like glycoprotein FCGBP marks progenitor cells in tissues of endodermal origin. Stem Cells 30: 1999-2009, 2012.
9. Harada N, Iijima S, Kobayashi K, Yoshida T, Brown WR, Hibi T, Oshima A and Morikawa M: Human IgGFc binding protein (FcgammaBP) in colonic epithelial cells exhibits mucin-like structure. J Biol Chem 272: 15232-15241, 1997.
10. Selbach M and Mann M: Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods 3: 981-983, 2006.
11. Wang A, Wu L, Lin J, Han L, Bian J, Wu Y, Robson SC, Xue L, Ge Y, Song X, et al: Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun 9: 894, 2018.
12. Zhou C, Chen H, Han L, Xue F, Wang A and Liang Y: Screening of genes related to lung cancer caused by smoking with RNA-Seq. Eur Rev Med Pharmacol Sci 18: 117-125, 2014.
13. Xiong L, Wen Y, Miao X and Yang Z: NTSE and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res 355: 365-374, 2014.
14. Gazi MH, He M, Cheville JC and Young CY: Downregulation of IgG Fc binding protein (Fc gammaBP) in prostate cancer. Cancer Biol Ther 7: 70-75, 2008.
15. O`Donovan N, Fischer A, Abdo EM, Simon F, Peter HJ, Gerber H, Buerger U and Marti U: Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas. J Endocrinol 174: 517-524, 2002.
16. Choi CH, Choi JJ, Park YA, Lee YY, Song SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, et al: Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: Expression of GRIA2 predicts better survival. Br J Cancer 107: 91-99, 2012.
17. Wang Y, Liu Y, Liu H, Zhang Q, Song H, Tang J, Fu J and Wang X: FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients. Oncotarget 8: 86503-86514, 2017.
18. Witzmann FA, Arnold RJ, Bai F, Hrnciriova P, Kimpel MW, Mechref YS, McBride WJ, Novotny MV, Pedrick NM, Ringham HN, et al: A proteomic survey of rat cerebral cortical synaptosomes. Proteomics 5: 2177-2201, 2005.
19. Grant, SG: The synapse proteome and phosphoproteome: a new paradigm for synapse biology. Biochem Soc Trans 34 (Pt 1): 59-63, 2006.
20. Dong S, Hao H, Mao Y, Li X and Dong L: A risk score model for the prediction of osteosarcoma metastasis. FEBS Open Bio 9: 519-526, 2019.
21. Kim M, Lee S, Yang SK, Song K and Lee I: Differential expression in histologically normal crypts of ulcerative colitis suggests primary crypt disorder. Oncol Rep 16: 663-670, 2006.
22. Risques RA, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdle KV, Lindor KD, et al: Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res 71: 1669-1679, 2011.
23. Lee S, Bang S, Song K and Lee I: Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep 16: 747-754, 2006.
24. Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L and Pei HP: Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis. Oncol Lett 6: 353-358, 2013.
et al: Molecular characteristics of circulating tumor cells in colorectal cancer. J Cancer 10: 5883-5890, 2019.

26. Ma R, Jing C, Zhang Y, Cao H, Liu S, Wang Z, Chen D, Zhang J, Wu Y, Wu J, et al: The somatic mutation landscape of Chinese Colorectal Cancer. J Cancer 11: 1038-1046, 2020.

27. Qi C, Hong L, Cheng Z and Yin Q: Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis. Oncol Lett 11: 568-574, 2016.

28. Bendas G and Borsig L: Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012: 676731, 2012.

29. Onstenk W, Siewerts AM, Mostert B, Lalmahomed Z, Bolt-de Vries JB, van Galen A, Smid M, Kraan J, Van M, de Weerd V, et al: Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget 7: 59058-59069, 2016.

30. Znaleasing et al: Transcriptional responses in the murine spleen after toxoplasma gondii infection: inflammasome and mucus-associated genes. Int J Mol Sci 18: 1245, 2017.

31. Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GM, Schütte A, van der Post S, Svensson F, Rodriguez-Piñeiro AM, Nyström EE, et al: The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. ImmunoL Rev 260: 8-20, 2014.

32. Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F and Tan HB: Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett 470: 126-133, 2020.

33. Picard E, Verschoor CP, Ma GW and Pawelec G: Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol 3: 110648, 2020.

34. Zhang GL, Pan LL, Huang T and Wang JH: The transcriptome difference between colorectal tumor and normal tissues revealed by single-cell sequencing. J Cancer 10: 3124-3129, 2019.

35. Ma R, Jing C, Zhang Y, Cao H, Liu S, Wang Z, Chen D, Zhang J, Wu Y, Wu J, et al: The somatic mutation landscape of Chinese Colorectal Cancer. J Cancer 11: 1038-1046, 2020.

36. Qi C, Hong L, Cheng Z and Yin Q: Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis. Oncol Lett 11: 568-574, 2016.

37. Bendas G and Borsig L: Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012: 676731, 2012.

38. Onstenk W, Siewerts AM, Mostert B, Lalmahomed Z, Bolt-de Vries JB, van Galen A, Smid M, Kraan J, Van M, de Weerd V, et al: Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget 7: 59058-59069, 2016.

39. Znaleasing et al: Transcriptional responses in the murine spleen after toxoplasma gondii infection: inflammasome and mucus-associated genes. Int J Mol Sci 18: 1245, 2017.

40. Skrzypczak M, Gorycka K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 5: e13091, 2010.

41. Nutterman DA, Alon U, Sierk AJ and Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 61: 3124-3130, 2001.

42. Hong Y, Downey T, Eu KW, Koh PK and Cheah PY: A’metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeuticas. Clin Exp Metastasis 27: 83-90, 2010.

43. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emmons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 49: 1024-1034, 2010.

44. Chatterjee A, Anh A, Rodger EJ, Stockwell PA and Eccles MR: A guide for designing and analyzing RNA-Seq data. Methods Mol Biol 1783: 55-80, 2018.

45. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res 77: e018-e019, 2017.

46. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Astor JC, Rodig S, et al: Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol 17: 174, 2016.

47. Aran D, Sirota M and Butte AJ: Systematic pan-cancer analysis of tumour purity. Nat Commun 6: 8971, 2015.

48. Siemens NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF and Szustakowski JD: Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One 12: e0179726, 2017.

49. Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J and Flign SP: Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 5: 18, 2017.

50. Sousa S and Mäitäät J: The role of tumour-associated macrophages in bone metastasis. J Bone Oncol 5: 135-138, 2016.

51. Siskova A, Cervena K, Kral J, Hucl T, Vodicka P and Vymetalkova V: Colorectal adenomas-genetics and searching phages in bone metastasis. J Bone Oncol 5: 135-138, 2016.

52. Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB and Qu C: The Prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep 10: 3360, 2020.

53. Dalal N, Jalandra R, Sharma M, Prakash H, Makharia GK, Solanki PR, Singh R and Kumar A: Omics technologies for improved diagnosis and treatment of colorectal cancer: Technical advancement and major perspectives. Biomed Pharmacother 131: 110468, 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.